# Sabine Linn

Source: https://onco.cc/people/sabine-linn/  
OnCo record `sabine-linn` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sabine Linn is a breast oncologist testing DNA-damaging chemotherapy in BRCA-like breast cancer.

## Summary

Sabine Linn is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Utrecht. Her specialisms are breast cancer, BRCA-like tumours and neoadjuvant trials, with a focus on BRCA1/BRCA2 and homologous recombination deficiency in triple-negative disease. She leads breast cancer trials at NKI, including studies of high-dose alkylating chemotherapy in BRCA1-like tumours and of neoadjuvant immunotherapy. Her papers include the TRAIN-2 phase 3 trial of neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade and its three-year follow-up, and a study of stromal tumour-infiltrating lymphocytes in young, node-negative, triple-negative patients who received no systemic therapy. Her publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical Oncologist and Group Leader, Netherlands Cancer Institute; Professor, Utrecht
- Specialisms: Breast cancer; BRCA-like tumours; Neoadjuvant trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- institutions: [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- terms: [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/)

---
JSON: https://onco.cc/api/v1/entities/sabine-linn.json